Literature DB >> 23648670

Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia.

F Stölzel1, U Platzbecker, B Mohr, C Röllig, J M Middeke, C Thiede, M Füssel, M Hänel, M Schaich, G Ehninger, J Schetelig, M Bornhäuser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23648670     DOI： 10.1038/leu.2013.142

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.

Authors:  X Chen; L F Newell; H Xie; R B Walter; J M Pagel; V K Sandhu; P S Becker; P C Hendrie; J L Abkowitz; F R Appelbaum; E H Estey
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

2.  Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

Authors:  M A Kharfan-Dabaja; M Labopin; A Bazarbachi; R M Hamladji; D Blaise; G Socié; B Lioure; A Bermudez; L Lopez-Corral; R Or; W Arcese; N Fegueux; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-06-30       Impact factor: 5.483

3.  Progressive Dispersion of Azole Resistance in Aspergillus fumigatus: Fatal Invasive Aspergillosis in a Patient with Acute Myeloid Leukemia Infected with an A. fumigatus Strain with a cyp51A TR46 Y121F M172I T289A Allele.

Authors:  Susann Rößler; Oliver Bader; Friedrich Stölzel; Ulrich Sommer; Birgit Spiess; Stephan Geibel; Dieter Buchheidt; Uwe Groß; Gustavo Baretton; Enno Jacobs; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

4.  Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.

Authors:  J M Middeke; R Herbst; S Parmentier; G Bug; M Hänel; G Stuhler; K Schäfer-Eckart; W Rösler; S Klein; W Bethge; U Bitz; B Büttner; H Knoth; N Alakel; M Schaich; A Morgner; M Kramer; K Sockel; M von Bonin; F Stölzel; U Platzbecker; C Röllig; C Thiede; G Ehninger; M Bornhäuser; J Schetelig
Journal:  Leukemia       Date:  2015-08-18       Impact factor: 11.528

5.  Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma.

Authors:  S Fuji; H Fujiwara; N Nakano; A Wake; Y Inoue; T Fukuda; M Hidaka; Y Moriuchi; T Miyamoto; N Uike; J Taguchi; T Eto; T Tomoyose; T Kondo; A Yamanoha; T Ichinohe; Y Atsuta; A Utsunomiya
Journal:  Bone Marrow Transplant       Date:  2015-11-02       Impact factor: 5.483

6.  Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.

Authors:  Cindy M Pabon; Zhiguo Li; Therese Hennig; Carlos de Castro; Jadee L Neff; Mitchell E Horwitz; Thomas W LeBlanc; Gwynn D Long; Richard D Lopez; Anthony D Sung; Nelson Chao; Cristina Gasparetto; Stefanie Sarantopoulos; Donna B Adams; Harry Erba; David A Rizzieri
Journal:  Blood Cancer J       Date:  2021-05-16       Impact factor: 11.037

7.  Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse.

Authors:  Johannes Schetelig; Jan Moritz Middeke; Katja Sockel; Friedrich Stölzel; Franziska Hönl; Henning Baldauf; Christoph Röllig; Martin Wermke; Malte von Bonin; Raphael Teipel; Cornelia Link-Rachner; Kalina Brandt; Frank Kroschinsky; Mathias Hänel; Anke Morgner; Christian Klesse; Gerhard Ehninger; Uwe Platzbecker; Martin Bornhäuser
Journal:  Cancer Manag Res       Date:  2022-02-15       Impact factor: 3.989

8.  A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML).

Authors:  Silvia Park; Daehun Kwag; Tong Yoon Kim; Jong Hyuk Lee; Joon Yeop Lee; Gi June Min; Sung Soo Park; Seung-Ah Yahng; Young-Woo Jeon; Seung-Hwan Shin; Jae-Ho Yoon; Sung-Eun Lee; Byung Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Jong Wook Lee; Hee-Je Kim
Journal:  Ther Adv Hematol       Date:  2022-03-23

9.  Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.

Authors:  Christina Rautenberg; Friedrich Stölzel; Thomas Schroeder; Jan Moritz Middeke; Christoph Röllig; Matthias Stelljes; Verena Gaidzik; Michael Lauseker; Oliver Kriege; Mareike Verbeek; Julia Marie Unglaub; Felicitas Thol; Stefan W Krause; Mathias Hänel; Charlotte Neuerburg; Vladan Vucinic; Christian-Friedrich Jehn; Julia Severmann; Maxi Wass; Lars Fransecky; Jens Chemnitz; Udo Holtick; Kerstin Schäfer-Eckart; Josephine Schröder; Sabrina Kraus; William Krüger; Ulrich Kaiser; Sebastian Scholl; Kathrin Koch; Lea Henning; Guido Kobbe; Rainer Haas; Nael Alakel; Maximilian-Alexander Röhnert; Katja Sockel; Maher Hanoun; Uwe Platzbecker; Tobias A W Holderried; Anke Morgner; Michael Heuser; Tim Sauer; Katharina S Götze; Eva Wagner-Drouet; Konstanze Döhner; Hartmut Döhner; Christoph Schliemann; Johannes Schetelig; Martin Bornhäuser; Ulrich Germing
Journal:  Blood Cancer J       Date:  2021-10-04       Impact factor: 11.037
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.